研究报告 Research Report 2 Sep 2025 中国生物制药 Sino Biopharmaceutical (1177 HK) 1H25 业绩回顾：创新品种稳健放量，收入利润双位数增长 1H25 results review: robust innovative drug sales growth; revenue/profit achieved double-digit growth [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$8.61 目标价 HK$10.87 HTI ESG 1.3-2.0-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$161.53bn / US$20.72bn 日交易额 (3 个月均值) US$149.05mn 发行股票数目 18,761mn 自由流通股 (%) 52% 1 年股价最高最低值 HK$8.61-HK$2. ...